Business Context and Reporting Period
This Form 6-K filing is submitted by Midatech Pharma PLC (not Biodexa Pharmaceuticals Plc as indicated in the metadata) for the month of March 2023, dated March 10, 2023. The filing serves to announce a correction of typographical errors in the Company's Circular and Notice of General Meeting regarding a shareholder meeting scheduled for March 24, 2023.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a procedural announcement regarding a press release and does not contain financial statements or performance data.
Material Changes
There are no material financial changes reported in this filing. The only material update is the correction of typographical errors in previously issued shareholder communications.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, or outlook. It explicitly states that the attached press release (Exhibit 99.1) is furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, nor incorporated by reference into other filings.
Key Facts for Investor Verification
- Verify the corrected text in the Circular and Notice of General Meeting for the March 24, 2023, shareholder meeting.
- Confirm that the press release attached as Exhibit 99.1 is not considered a formal filing under the Exchange Act.
- Note that this filing contains no financial performance data for the period.